| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/19/2006 | US7109183 Phosphohalohydrins, process for the production thereof and use thereof |
| 09/19/2006 | US7109179 Methods and compositions comprising DNA damaging agents and p53 |
| 09/19/2006 | US7109171 Reducing FSH levels by administering a GnRH antagonist to reduce both plasma FSH and LH levels; treating prostatic intraepithelial neoplasia, pedophilia, infertility, vaginal bleeding; in vitro fertilization and male contraception |
| 09/19/2006 | US7109167 Tetrapeptide |
| 09/19/2006 | US7109166 A piperazine-somatostatin analog in sustained release ionic conjugate with lactic acid-glycolic acid-tartaric acid copolymer; for therapy of gastrointestinal disorders, such as Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis |
| 09/19/2006 | US7109164 Administering compounds such as 3-[[3,5-dibromo-[4-hydroxy-3-(1-methylethyl)phenoxy]-phenyl]amino]-3-oxopropanoic acid for therapy of obesity, hypercolesterolemia atherosclerosis, depression, osteoporosis, hypothyroidism, goiter, glaucoma, cardiac arrhythmia, congestive heart failure, or a skin disorder |
| 09/19/2006 | US7109160 Peptides containing the motif IGD and their use as cell migration modulators |
| 09/19/2006 | US7109159 Administering to a mammal an active agent selected from the group consisting of leptin; a mutein of leptin fusion protein, fusion protein for inhibiting tumor cell proliferation in mammals |
| 09/19/2006 | US7109031 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
| 09/19/2006 | US7109029 Adenoviral transcription of colony stimulating factor; gene expression inhibition; antitumor agents; antiproliferative agents; tissue engineering |
| 09/19/2006 | US7109026 Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment |
| 09/19/2006 | US7108981 Administering monoclonal antibody that specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), wherein the monoclonal antibody is produced by a hybridoma in a pharmaceutically acceptable carrier for therapy of Kaposi's sarcoma-associated herpesvirus infection |
| 09/19/2006 | US7108871 Isoflavones and saponins in defined ratios, menopause, cancer |
| 09/19/2006 | US7108868 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
| 09/19/2006 | US7108845 Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents |
| 09/19/2006 | US7108844 Use of stabilized oligonucleotides for preparing a medicament with antitumor activity |
| 09/19/2006 | CA2255664C Selenophene anti-tumor agents |
| 09/19/2006 | CA2140989C Phenyl-substituted alkylcarboguanidides carrying perfluoroalkyl groups, a process for their preparation, their use as a medicament or diagnosticagent, and a medicament containing them |
| 09/14/2006 | WO2006096807A1 Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| 09/14/2006 | WO2006096785A1 Quinoxaline dihydrohalide dihydrates and synthetic methods therefor |
| 09/14/2006 | WO2006096491A2 Anti-ctla-4 antibody compositions |
| 09/14/2006 | WO2006096481A1 Use of phenylacetyl-derivatives for the manufacture of a medicament to treat von hippel-lindau (vhl) disease |
| 09/14/2006 | WO2006096325A1 Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin |
| 09/14/2006 | WO2006096073A1 High pressure processing of metal ion lactoferrin |
| 09/14/2006 | WO2006095897A1 Screening method |
| 09/14/2006 | WO2006095798A1 Anticancer composition for oral use comprising liposome containing phytosterols and prevention or treatment for cancer using the liposome |
| 09/14/2006 | WO2006095783A1 Novel hsp90 inhibitor |
| 09/14/2006 | WO2006095713A1 Inhibitor of plasminogen activator inhibitor-1 |
| 09/14/2006 | WO2006095708A1 Porphyrin compound and use thereof |
| 09/14/2006 | WO2006095704A1 Method of treating liver cancer |
| 09/14/2006 | WO2006095636A1 Novel compound selectively activated at target site and utilization of the same |
| 09/14/2006 | WO2006095446A1 Methods for damaging cells using effector functions of anti-gfra1 antibodies |
| 09/14/2006 | WO2006095270A1 Combination anticancer therapy or om-174 and pharmaceutical compositions therefor |
| 09/14/2006 | WO2006095267A1 Compositions for the treatment of tumour pathologies, comprising internalin b (in1b) of listeria monocytogene protein or a fragment thereof |
| 09/14/2006 | WO2006095185A1 39-desmethoxy derivatives of rapamycin |
| 09/14/2006 | WO2006095173A2 Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| 09/14/2006 | WO2006095159A1 (imidazolo-5-yl)-2-anilo-pyrimidines as agents for the inhibition of cell proliferation |
| 09/14/2006 | WO2006095139A2 Cancer treatment using specific 3,6,9-substituted acridines |
| 09/14/2006 | WO2006094971A1 Combination of interleukin-6 antagonists and antiproliferative drugs |
| 09/14/2006 | WO2006094917A2 Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
| 09/14/2006 | WO2006094916A1 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| 09/14/2006 | WO2006094828A2 Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor |
| 09/14/2006 | WO2006094704A2 Natural ligand of g protein coupled receptor rcc356 and uses thereof |
| 09/14/2006 | WO2006094626A1 Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
| 09/14/2006 | WO2006094604A1 Tetrahydro- and dihydroquinazolinones |
| 09/14/2006 | WO2006094600A1 Substituted tetrahydropyrroloquinoline derivatives as kinase modulators, especially tyrosine kinase and raf kinase modulators |
| 09/14/2006 | WO2006094539A1 Methods and compositions for the treatment of cancer |
| 09/14/2006 | WO2006094414A1 Non invasive method for prevention and treatment of cancer |
| 09/14/2006 | WO2006094406A1 Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof |
| 09/14/2006 | WO2006094384A1 Use of interleukin 17e for the treatment of cancer |
| 09/14/2006 | WO2006075172A3 Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2 |
| 09/14/2006 | WO2006074071A8 Framework residue substituted humanized col-1 antibodies and their use |
| 09/14/2006 | WO2006070432A3 Anti-tumoral immunogenic peptides and vaccine thereof |
| 09/14/2006 | WO2006069812A3 Retrotransposon inhibition in therapy |
| 09/14/2006 | WO2006067445A3 Csf-1r kinase inhibitors |
| 09/14/2006 | WO2006061242A3 Use of pta peptides for stratification of individuals having cancer |
| 09/14/2006 | WO2006051290A3 Compounds for treating protein-kinase mediated disorders |
| 09/14/2006 | WO2006020684A3 Methods of regulating differentiation and treating of multiple myeloma |
| 09/14/2006 | US20060205951 New crystal modification of torasemide |
| 09/14/2006 | US20060205809 Pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 09/14/2006 | US20060205795 Cancer treatment with epothilones |
| 09/14/2006 | US20060205763 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 09/14/2006 | US20060205762 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 09/14/2006 | US20060205734 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/14/2006 | US20060205723 5-(Substituted oxazolyl- or thiazolyl-ethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 09/14/2006 | US20060205712 e.g. N-[2-[4-(2-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl -quinolin-8-yloxy-methyl)-benzensulfonamide trifluoroacetate; antiinflammatory agent; asthma, chronic bronchitis, allergic rhinitis, obstructive pulmonary disease (COPD) |
| 09/14/2006 | US20060205708 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/14/2006 | US20060205707 adenosine triphosphate inhibitors used for the treatment of cancer; anticarcinogenic agents |
| 09/14/2006 | US20060205676 I kappa B kinase beta inhibitors that are 2-amino-4,6-disubstituted nicotinic acid ester analogs; antiinflammatory, antitumor and antiischemic effects; asthma; nuclear factor kappa B inhibitors; 7-(2-hydroxyphenyl)-5-(3-piperidinyl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one |
| 09/14/2006 | US20060205673 2-Amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives |
| 09/14/2006 | US20060205667 Wt1 substitution pepides |
| 09/14/2006 | US20060205665 Non-basic amino acid sequence transporter peptide conjugated to biological effector; translocation across the membrane of eukaryotic cells |
| 09/14/2006 | US20060205659 Peptide radical having 5-25 amino acids with its N-terminus capped with a monoester of fumaric acid; used to treat autoimmune diseases, mitochondrial diseases, and NF-kappaB mediated diseases and in transplantation medicine |
| 09/14/2006 | US20060205655 Nucleic acids encoding (poly) peptides having CHIPS activity |
| 09/14/2006 | US20060205074 Neural progenitor cells derived from whole bone marrow |
| 09/14/2006 | US20060205018 Polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides; use in therapy |
| 09/14/2006 | US20060205016 Protein a based binding domains with desirable activities |
| 09/14/2006 | US20060204982 Novel compositions and methods for cancer |
| 09/14/2006 | US20060204593 Superoxide anion decomposing agent |
| 09/14/2006 | US20060204591 Treatment of mucosal membranes |
| 09/14/2006 | US20060204523 Flavivirus vaccine delivery system |
| 09/14/2006 | US20060204516 Compositions and methods for enhancing the immunogenicity of antigens |
| 09/14/2006 | US20060204510 Bv8 nucleic acids and polypeptides with mitogenic activity |
| 09/14/2006 | US20060204501 Drug for cancer therapy |
| 09/14/2006 | US20060204459 Use of tyrosine inhibitors for whitening human skin and treating melanocyted dysfunction associated diseases |
| 09/14/2006 | DE102005011111A1 Pharmaceutical composition comprising dendritic cells, useful for treating tumors, especially of the skin, where cells are loaded with animal toxins, formulated with a homeopathic component |
| 09/14/2006 | DE102005011058A1 Substituierte Tetrahydro-pyrrolo-chinolinderivate Substituted tetrahydro-pyrrolo-quinoline derivatives |
| 09/14/2006 | CA2602010A1 Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin |
| 09/14/2006 | CA2601978A1 Quinoxaline dihydrohalide dihydrates and synthetic methods therefor |
| 09/14/2006 | CA2600836A1 Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
| 09/14/2006 | CA2600640A1 39-desmethoxy derivatives of rapamycin |
| 09/14/2006 | CA2600637A1 Tetrahydro- and dihydroquinazolinones |
| 09/14/2006 | CA2600630A1 Substituted tetrahydropyrroloquinoline derivatives as kinase modulators, especially tyrosine kinase and raf kinase modulators |
| 09/14/2006 | CA2600558A1 Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane |
| 09/14/2006 | CA2600460A1 High pressure processing of metal ion lactoferrin |
| 09/14/2006 | CA2600434A1 Anti-ctla-4 antibody compositions |
| 09/14/2006 | CA2600370A1 Bioactive fus1 peptides and nanoparticle-polypeptide complexes |
| 09/14/2006 | CA2600358A1 Method for treatment of hepatic cancer |
| 09/14/2006 | CA2599547A1 Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| 09/14/2006 | CA2598899A1 Novel hsp90 inhibitor |